OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival

European Journal of Immunology

Volumn 41, Issue 4, 2011, Pages 1024-1034

  Vasilevsky, Nicole A ^a,b   Ruby, Carl E ^a   Hurlin, Peter J ^c   Weinberg, Andrew D ^a,d  

^a PROVIDENCE PORTLAND MEDICAL CENTER   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c SHRINERS HOSPITAL FOR CHILDREN   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Mnt; Mxd4; OX40; T cells

Indexed keywords

CD134 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MYC PROTEIN; NUCLEIC ACID BINDING PROTEIN; PROTEIN MNT; PROTEIN MXD4; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; FEMALE; IMMUNOSTIMULATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; T LYMPHOCYTE; UPREGULATION;

ANIMALS; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; CELL LINE; CELL SURVIVAL; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; MICE; PHOSPHOSERINE; PROTO-ONCOGENE PROTEINS C-MYB; RECEPTORS, OX40; REPRESSOR PROTEINS; RNA, SMALL INTERFERING; T-LYMPHOCYTES;

EID: 79953063925     PISSN: 00142980     EISSN: 15214141     Source Type: Journal    
DOI: 10.1002/eji.201040449     Document Type: Article

References (64)

1. Taraban, V. Y., Rowley, T. F., O'Brien, L., Chan, H. T., Haswell, L. E., Green, M. H., Tutt, A. L. et al., Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses. Eur. J. Immunol. 2002. 32: 3617-3627.
2. + T cell responses. J. Immunol. 1998. 161: 6510-6517.
3. Maxwell, J. R., Weinberg, A., Prell, R. A. and Vella, A. T., Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J. Immunol. 2000. 164: 107-112.
4. Watts, T. H. and DeBenedette, M. A., T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 1999. 11: 286-293.2
5. + T cells to recall tumor-associated antigen. J. Immunol. 2005. 175: 3534-3541.
6. ++ memory T cells and their capacity for secondary expansion. J. Immunol. 2005. 175: 1665-1676.
7. Godfrey, W. R., Fagnoni, F. F., Harara, M. A., Buck, D. and Engleman, E. G., Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J. Exp. Med. 1994. 180: 757-762.
8. + T cell responses. J. Immunol. 2006. 177: 4464-4472.
9. + T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J. Immunol. 2007. 179: 7244-7253.
10. Weinberg, A. D., Vella, A. T. and Croft, M., OX-40: life beyond the effector T cell stage. Semin. Immunol. 1998. 10: 471-480.
11. +(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. J. Immunol. 2001. 167: 6804-6811.
12. + T cell survival. J. Immunol. 2008. 180: 2140-2148.
13. Prell, R. A., Evans, D. E., Thalhofer, C., Shi, T., Funatake, C. and Weinberg, A. D., OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent. J. Immunol. 2003. 171: 5997-6005.
14. Weinberg, A. D., Wegmann, K. W., Funatake, C. and Whitham, R. H., Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J. Immunol. 1999. 162: 1818-1826.
15. June, C. H., Bluestone, J. A., Nadler, L. M. and Thompson, C. B., The B7 and CD28 receptor families. Immunol. Today 1994. 15: 321-331.
16. Krummel, M. F. and Allison, J. P., CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J. Exp. Med. 1995. 182: 459-465.
17. Thompson, C. B. and Allison, J. P., The emerging role of CTLA-4 as an immune attenuator. Immunity 1997. 7: 445-450.
18. Grandori, C., Cowley, S. M., James, L. P. and Eisenman, R. N., The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol. 2000. 16: 653-699.
19. Luscher, B., Function and regulation of the transcription factors of the Myc/Max/Mad network. Gene 2001. 277: 1-14.
20. Hann, S. R., Thompson, C. B. and Eisenman, R. N., c-myc oncogene protein synthesis is independent of the cell cycle in human and avian cells. Nature 1985. 314: 366-369.
21. Rabbitts, P. H., Watson, J. V., Lamond, A., Forster, A., Stinson, M. A., Evan, G., Fischer, W. et al., Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J. 1985. 4: 2009-2015.
22. Ayer, D. E. and Eisenman, R. N., A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes Dev. 1993. 7: 2110-2119.
23. Hurlin, P. J., Queva, C. and Eisenman, R. N., Mnt: a novel Max-interacting protein and Myc antagonist. Curr. Top. Microbiol. Immunol. 1997. 224: 115-121.
24. Knoepfler, P. S. and Eisenman, R. N., Sin meets NuRD and other tails of repression. Cell 1999. 99: 447-450.
25. Amati, B., Brooks, M. W., Levy, N., Littlewood, T. D., Evan, G. I. and Land, H., Oncogenic activity of the c-Myc protein requires dimerization with Max. Cell 1993. 72: 233-245.
26. Blackwood, E. M., Luscher, B. and Eisenman, R. N., Myc and Max associate in vivo. Genes Dev. 1992. 6: 71-80.
27. Ayer, D. E., Kretzner, L. and Eisenman, R. N., Mad: a heterodimeric partner for Max that antagonizes Myc transcriptional activity. Cell 1993. 72: 211-222.
28. Nilsson, J. A., Maclean, K. H., Keller, U. B., Pendeville, H., Baudino, T. A. and Cleveland, J. L., Mnt loss triggers Myc transcription targets, proliferation, apoptosis, and transformation. Mol. Cell. Biol. 2004. 24: 1560-1569.
29. Gehring, S., Rottmann, S., Menkel, A. R., Mertsching, J., Krippner-Heidenreich, A. and Luscher, B., Inhibition of proliferation and apoptosis by the transcriptional repressor Mad1. Repression of Fas-induced caspase-8 activation. J. Biol. Chem. 2000. 275: 10413-10420.
30. Bejarano, M. T., Albihn, A., Cornvik, T., Brijker, S. O., Asker, C., Osorio, L. M. and Henriksson, M., Inhibition of cell growth and apoptosis by inducible expression of the transcriptional repressor Mad1. Exp. Cell Res. 2000. 260: 61-72.
31. Walker, W., Zhou, Z. Q., Ota, S., Wynshaw-Boris, A. and Hurlin, P. J., Mnt-Max to Myc-Max complex switching regulates cell cycle entry. J. Cell Biol. 2005. 169: 405-413.
32. Buckley, A. F., Kuo, C. T. and Leiden, J. M., Transcription factor LKLF is sufficient to program T cell quiescence via a c-Myc-dependent pathway. Nat. Immunol. 2001. 2: 698-704.
33. Grumont, R., Lock, P., Mollinari, M., Shannon, F. M., Moore, A. and Gerondakis, S., The mitogen-induced increase in T cell size involves PKC and NFAT activation of Rel/NF-kappaB-dependent c-myc expression. Immunity 2004. 21: 19-30.
34. Lindsten, T., June, C. H. and Thompson, C. B., Multiple mechanisms regulate c-myc gene expression during normal T cell activation. EMBO J. 1988. 7: 2787-2794.
35. Huang, C. Y., Bredemeyer, A. L., Walker, L. M., Bassing, C. H. and Sleckman, B. P., Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse. Eur. J. Immunol. 2008. 38: 342-349.
36. Trumpp, A., Refaeli, Y., Oskarsson, T., Gasser, S., Murphy, M., Martin, G. R. and Bishop, J. M., c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature 2001. 414: 768-773.
37. Dose, M., Sleckman, B. P., Han, J., Bredemeyer, A. L., Bendelac, A. and Gounari, F., Intrathymic proliferation wave essential for Valpha14+ natural killer T cell development depends on c-Myc. Proc. Natl. Acad. Sci. USA 2009. 106: 8641-8646.
38. Wilson, A., Murphy, M. J., Oskarsson, T., Kaloulis, K., Bettess, M. D., Oser, G. M., Pasche, A. C. et al., c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev. 2004. 18: 2747-2763.
39. Weinberg, A. D., Evans, D. E., Thalhofer, C., Shi, T. and Prell, R. A., The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement. J. Leukoc. Biol. 2004. 75: 962-972.
40. Fabbro, M. and Henderson, B. R., Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp. Cell Res. 2003. 282: 59-69.
41. Fornerod, M., Ohno, M., Yoshida, M. and Mattaj, I. W., CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 1997. 90: 1051-1060.
42. Xiao, Z., Latek, R. and Lodish, H. F., An extended bipartite nuclear localization signal in Smad4 is required for its nuclear import and transcriptional activity. Oncogene 2003. 22: 1057-1069.
43. Grinberg, A. V., Hu, C. D. and Kerppola, T. K., Visualization of Myc/Max/Mad family dimers and the competition for dimerization in living cells. Mol. Cell. Biol. 2004. 24: 4294-4308.
44. Brunner, M. C., Chambers, C. A., Chan, F. K., Hanke, J., Winoto, A. and Allison, J. P., CTLA-4-mediated inhibition of early events of T cell proliferation. J. Immunol. 1999. 162: 5813-5820.
45. Takesono, A., Finkelstein, L. D. and Schwartzberg, P. L., Beyond calcium: new signaling pathways for Tec family kinases. J. Cell Sci. 2002. 115: 3039-3048.
46. Greenfield, E. A., Nguyen, K. A. and Kuchroo, V. K., CD28/B7 costimulation: a review. Crit. Rev. Immunol. 1998. 18: 389-418.
47. Pandiyan, P., Gartner, D., Soezeri, O., Radbruch, A., Schulze-Osthoff, K. and Brunner-Weinzierl, M. C., CD152 (CTLA-4) determines the unequal resistance of Th1 and Th2 cells against activation-induced cell death by a mechanism requiring PI3 kinase function. J. Exp. Med. 2004. 199: 831-842.
48. + T cells for robust effector function. J. Immunol. 2004. 173: 3002-3012.
49. + T cell responses by OX40. J. Immunol. 2004. 172: 4821-4825.
50. De Smedt, T., Smith, J., Baum, P., Fanslow, W., Butz, E. and Maliszewski, C., Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo. J. Immunol. 2002. 168: 661-670.
51. Hurlin, P. J., Queva, C. and Eisenman, R. N., Mnt, a novel Max-interacting protein is coexpressed with Myc in proliferating cells and mediates repression at Myc binding sites. Genes Dev. 1997. 11: 44-58.
52. Zhu, J., Blenis, J. and Yuan, J., Activation of PI3K/Akt and MAPK pathways regulates Myc-mediated transcription by phosphorylating and promoting the degradation of Mad1. Proc. Natl. Acad. Sci. USA 2008. 105: 6584-6589.
53. Egen, J. G., Kuhns, M. S. and Allison, J. P., CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 2002. 3: 611-618.
54. + T cells that inhibits interleukin-2 secretion but allows Bcl-X(L) induction. J. Immunol. 1998. 160: 12-15.
55. Fife, B. T., Griffin, M. D., Abbas, A. K., Locksley, R. M. and Bluestone, J. A., Inhibition of T cell activation and autoimmune diabetes using a B cell surface-linked CTLA-4 agonist. J. Clin. Invest. 2006. 116: 2252-2261.
56. Rudolph, B., Hueber, A. O. and Evan, G. I., Reversible activation of c-Myc in thymocytes enhances positive selection and induces proliferation and apoptosis in vitro. Oncogene 2000. 19: 1891-1900.
57. Carding, S. and Reem, G. H., c-myc gene expression and activation of human thymocytes. Thymus 1987. 10: 219-229.
58. Murphy, D. J., Junttila, M. R., Pouyet, L., Karnezis, A., Shchors, K., Bui, D. A., Brown-Swigart, L. et al., Distinct thresholds govern Myc's biological output in vivo. Cancer Cell 2008. 14: 447-457.
59. Queva, C., McArthur, G. A., Iritani, B. M. and Eisenman, R. N., Targeted deletion of the S-phase-specific Myc antagonist Mad3 sensitizes neuronal and lymphoid cells to radiation-induced apoptosis. Mol. Cell. Biol. 2001. 21: 703-712.
60. Hemann, M. T., Bric, A., Teruya-Feldstein, J., Herbst, A., Nilsson, J. A., Cordon-Cardo, C. et al., Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature 2005. 436: 807-811.
61. Mitchell, K. O., Ricci, M. S., Miyashita, T., Dicker, D. T., Jin, Z., Reed, J. C. and El-Deiry, W. S., Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res. 2000. 60: 6318-6325.
62. Dezfouli, S., Bakke, A., Huang, J., Wynshaw-Boris, A. and Hurlin, P. J., Inflammatory disease and lymphomagenesis caused by deletion of the Myc antagonist Mnt in T cells. Mol. Cell. Biol. 2006. 26: 2080-9202.
63. + T cells. Immunity 2001. 15: 445-455.
64. Haskins, K., Kubo, R., White, J., Pigeon, M., Kappler, J. and Marrack, P., The major histocompatibility complex-restricted antigen receptor on T cells. I. Isolation with a monoclonal antibody. J. Exp. Med. 1983.157: 1149-1169.